Introduction
============

Hematopoietic cell transplantation (HCT), including bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT), is important in the treatment of hematologic malignancies and connective tissue diseases. As the number of patients receiving HCT has increased, reports on the association between neurological complications and HCT have also increased. Neurological complications after HCT may be caused by various factors, including the primary disease, post-transplant lymphoproliferative disease (PTLD), drug- or radiation-induced effects, and opportunistic infections due to immunosuppression. Chronic graft versus host disease (GVHD), which most often involves the skin, eyes, oral mucosa, lungs, gastrointestinal tract and liver, can also cause neurological complications. Although the National Institute of Health\'s working group on chronic GVHD acknowledges that the neuromuscular manifestation of chronic GVHD only involves the muscle, neuromuscular junctions, and peripheral nerves ([@B1]), the number of reported cases of chronic GVHD that involve the central nervous system (CNS-cGVHD) has increased in recent years. This paper reports a case of CNS-cGVHD that occurred at 19 months after PBSCT, which was performed to treat acute myeloid leukemia (AML). The correlations between the radiological and pathological characteristics are useful for diagnosing CNS-cGVHD. This paper discusses the present case in detail and refers to previous studies.

Case Report
===========

A 46-year-old right-handed woman was admitted to the hospital with pancytopenia. She had received chemotherapy (cyclophosphamide, doxorubicin, and 5-fluorouracil) 8 years previously for a left breast carcinoma. Bone-marrow aspiration and biopsy revealed hypercellular marrow with an increased number of blasts (15.2%). The patient was therefore diagnosed with therapy-related myelodysplastic syndrome (t-MDS). She subsequently progressed to t-AML (French-American-British classification M0) and received idarubicin (IDR) and cytarabine (Ara-C) to induce remission. At five months after the initial diagnosis, the patient underwent allogeneic PBSCT (allo-PBSCT) from a one-allele mismatched related donor after preparation with cyclosporine A (CyA) and total body irradiation (TBI). Full engraftment was confirmed on day 16. The initial post-transplant course was complicated by acute oral, gastrointestinal tract, and skin GVHD that resolved after treatment with prednisolone (PSL), CyA, and methotrexate (MTX). At five months after PBSCT, the patient developed chronic pulmonary GVHD in the form of bronchiolitis obliterans organizing pneumonia (BOOP). She was treated with oral PSL, which was tapered after achieving a good result.

At 19 months after PBSCT, the patient developed headache, night sweats, difficulty writing due to shaking hands, and memory loss. Her blood test results were normal. Cerebrospinal fluid (CSF) studies revealed pleocytosis (33.3×10^6^/L), protein elevation (85 mg/dL), and low CSF glucose (45 mg/dL), while the patient was negative for oligoclonal IgG bands and malignant cells. Bacterial and fungal cultures, a CSF polymerase chain reaction (PCR) for the JC virus, and tests for *Toxoplasma gondii*, Cytomegalovirus, Herpes simplex, and Varicella zoster virus were all negative. Magnetic resonance imaging (MRI) revealed areas of confluent and asymmetrical hyperintensity on T2-weighted images (T2WI) and fluid-attenuated inversion recovery (FLAIR) in the bilateral cerebral white matter ([Fig. 1A](#g001){ref-type="fig"}). Gadolinium-enhanced MRI of the brain revealed multiple punctate and curvilinear lesions spreading from the deep cerebral region to the subcortical white matter, the pons, and the cerebellar vermis ([Fig. 1B and C](#g001){ref-type="fig"}). Furthermore, both diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps revealed diffuse areas of high-intensity ([Fig. 1D and E](#g001){ref-type="fig"}). MR angiography (MRA) and susceptibility-weighted imaging (SWI) revealed normal findings.

![Cranial MRI. (A) A T2-weighted image (TR/TE=3,000.0/80.0 ms). High-intensity plaque lesions are evident in the bilateral cerebral white matter, predominantly on the left side. (B, C) A gadolinium-enhanced T1-weighted image (TR/TE=6.0/2.3 ms). These lesions are enhanced with gadolinium, especially in the perivascular sites (red arrows). No gadolinium enhancement of the meninges was detected. (D, E) A diffusion-weighted imaging (DWI) and an apparent diffusion coefficient (ADC) map (b=1,000 s/mm^2^, TR/TE=5,000.0/65.0 ms). Both DWI and the ADC map show increased values in the involved areas. (F) A T2-weighted image (TR/TE=3,000.0/100.0 ms) after steroid pulse therapy. The high-intensity lesions of the white matter were significantly reduced. R: right](1349-7235-56-0363-g001){#g001}

Fourteen days after MRI, an open brain biopsy was performed to collect a piece of brain from the patient\'s left frontal lobe white matter. The biopsy revealed the perivascular infiltration of small, mature lymphocytes in the brain parenchyma, without any signs of inflammatory cell infiltration into the vessel walls. These infiltrates were mostly CD3- and CD8-positive on immunostaining. The formation of granulomas was observed in some portions of the examined brain tissue. *In situ* hybridization for Epstein-Barr Virus (EBV)-encoded small RNAs (EBERs) was negative ([Fig. 2](#g002){ref-type="fig"}). Furthermore, no findings indicated the recurrence of the primary disease. In view of these facts, we diagnosed the patient as having CNS-cGVHD.

![The immunohistological characteristics of brain tissue. A brain biopsy showing perivascular inflammation, which was predominantly located within the brain parenchyma. The inflammatory cells were mainly T lymphocytes with a cytotoxic T-cell immunophenotype, expressing CD3 and CD8. No EBV-encoded small RNA (EBER) transcripts were detected by*in situ* hybridization. Hematoxylin and Eosin staining demonstrated non-caseating granulomas containing lymphocytes, histiocytes, giant cells, and rare eosinophils. Original magnification, 100×.](1349-7235-56-0363-g002){#g002}

Treatment with three cycles of methylprednisolone pulse therapy (1,000 mg/day for 3 days) was initiated, which led to a dramatic improvement in the patient\'s cognitive and neuropsychiatric symptoms. Her brain MRI showed the shrinkage of the white matter lesions and the disappearance of the gadolinium-enhanced lesions ([Fig. 1F](#g001){ref-type="fig"}). She was subsequently placed on maintenance therapy with oral PSL and tacrolimus. Three months after the onset of symptoms, we confirmed the disappearance of almost all of her neurological symptoms.

Discussion
==========

The CNS can be the target organ of GVHD. Approximately 30 years previously, Rouah et al. first described the local infiltration of lymphocytes into the CNS in a study of the autopsied brains of GVHD patients ([@B2]). Similar findings have been reported in recent years using animal models of chronic GVHD ([@B3],[@B4]). Openshaw and Grauer et al. proposed the following six criteria for diagnosing CNS-cGVHD: the occurrence with chronic GVHD affecting other organs, neurological signs of CNS involvement without other explanation, corresponding brain MRI abnormalities, abnormal CSF studies (pleocytosis, elevated protein or immunoglobulin G, oligoclonal bands), a pathological brain biopsy or post-mortem examination, and a response to immunosuppressive therapy ([@B5],[@B6]). The patient in the present case met all of these criteria. The exact pathophysiology of chronic GVHD remains uncertain, and it is often difficult to distinguish chronic GVHD from other neurological complications. This may be one reason why only a few cases of CNS-cGVHD have been reported to date, despite the increasing number of transplantations that are being performed.

A total of 24 cases of CNS-cGVHD after HCT have been reported to date. The mean age at the onset of neurological complications was 32 years (range: 9-63 years), the male-to-female ratio was 1:0.7, and the median interval between the time of transplant and the onset of symptoms was 18 months (range: 2-220 months) ([@B7]-[@B22]). Although many of these patients suffered from chronic GVHD of other organs as well, some had chronic GVHD that only involved the CNS ([@B7]-[@B10]). The neurological symptoms were diverse, and included motor paralysis, ataxia, and convulsions. Some patients presented with only psychiatric symptoms and cognitive dysfunction ([@B9],[@B11],[@B12],[@B14]), whereas others presented with optic neuritis and myelitis, similar to the optic neuritis and myelitis induced by multiple sclerosis ([@B8],[@B13]).

Only 13 biopsy- or autopsy-confirmed cases have been reported ([Table](#t001){ref-type="table"}). The histological features can be categorized into three types: cerebral vasculitis, encephalitis, and demyelination. The most common feature is the infiltration of CD3-positive T cell-dominant inflammatory cells in the perivascular space or within the vessel wall, whereas only scattered infiltrates were observed in brain parenchyma. Most of these inflammatory cells were CD8-positive cytotoxic T cells. The infiltration of CD68-positive monocytes/microglia ([@B10]) and human leucocyte antigen (HLA)-DR-positive microglia has also been reported ([@B15]). The use of a short tandem repeat (STR) analysis ([@B14]) or a sex chromosome analysis ([@B10]) to demonstrate donor-derived lymphocyte infiltration has also been reported to be useful for diagnosing chronic GVHD.

###### 

The Characteristics of the Patients with Chronic GVHD of the Central Nervous System after HCT.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference\   Age/\         Primary\    Type of\      Post-HCT\        Other\                                  Radiological\                                        Pathological findings                                                                                                       Therapy        Outcome
  No.          Sex           disease     HCT           period\          cGVHD                                   findings                                                                                                                                                                                        
                                                       (months)                                                                                                                                                                                                                                                 
  ------------ ------------- ----------- ------------- ---------------- --------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -------------- ----------
  7            32/M          CML         BMT           18               none                                    ND                                                   perivascular monocytosis                                                                                                    ND             dead

  11           9/M           AA          BMT           8                none                                    CA                                                   perivascular CD3+ cell infiltration                                                                                         ND             dead

  13/F         ALL           BMT         3             lung GIT         abnormal signaling of cerebrum          perivascular CD3+ cell infiltration                  ND                                                                                                                          dead           

  12           43/M          CML         BMT           18               skin liver                              WM lesions                                           brain edema, hematoma, multifocal distribution of inflammatory infiltrations of blood vessel walls and perivascular areas   CPM PSL        improved

  14           18/F          AML         BMT           2                skin                                    leukoencepha lopathy; CA                             angiitis                                                                                                                    MP             Improved

  21           44/F          ATLL        allo- BMT     18               skin                                    infiltrating lesion in WM with CE                    parenchymal perivascular CD3+ cell infiltration                                                                             MP             Improved

  58/F         Ph^+^ B-ALL   allo- HCT   15            skin GIT         patchy WMHs                             leptomeningeal perivascular CD3+ cell infiltration   MP                                                                                                                          Improved       

  16           41/M          FL          allo- HCT     18               skin mouth eyes                         multiple round lesions with CE                       perivascular CD3+ cell infiltration, noncaseating granulomas                                                                Dex CyA        Improved

  15           56/M          NHL         allo- PBSCT   39               pharynx eyes skin liver                 multiple T2 WMHs                                     perivascular CD3+ cell infiltration, activation of microglia                                                                MP PSL MMF     worsened

  10           35/M          CML         allo- BMT     45               skin liver                              multiple T2 WMHs                                     microangiitis                                                                                                               PSL CPM MTX    improved

  28/F         AML           allo- BMT   37            none             multiple T2 WMHs with perivascular CE   angiitis                                             MP PSL CPM                                                                                                                  improved       

  20/M         SCID          allo- BMT   220           none             multiple T2 WMHs; CE at meninges        angiitis                                             Dex MP CPM                                                                                                                  improved       

  33/M         CLL           allo- BMT   24            skin liver GIT   CA                                      Parenchyma, leptomeningeal angiitis                  MP CPM                                                                                                                      improved       

  This case    46/F          AML         allo- PBSCT   19               lung                                    multiple T2 WMHs with perivascular CE                perivascular CD3+ cell infiltration, noncaseating granulomas                                                                MP PSL FK506   improved
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

M: male, F: female, AA: aplastic anemia, ATLL: adult-onset T-cell lymphoma, AML: acute myeloid leukemia, B-ALL: B-cell acute lymphoblastic leukemia, BMT: bone marrow transplantation, CA: cerebral atrophy, CDVP: combination therapy of cisplatin, dacarbazine, vinblastine, and prednisolone, CE: contrast enhancement, CHOP: combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone, CLL: chronic lymphocytic leukemia, CML: chronic myelocytic leukemia, CPM: cyclophosphamide, CyA: cyclosporin A, Dex: dexamethasone, FK506: tacrolimus, FL: follicular lymphoma, GIT: gastrointestinal tract, HCT: hematopoietic cell transplantation, HIAs: hyperintense areas, MMF: mycophenolate mofetil, MP: methylprednisolone, ND: not described, NHL: Non-Hodgkin lymphoma, WM: white matter, WMH: white matter hyperintensity, PBSCT: peripheral blood stem cell transplantation, PSL: prednisolone, SCID: severe combined immunodeficiency disease, T2: T2-weighted imaging

Brain MRI often revealed multiple hyperintense lesions, showing signs of healing, that were predominantly located in the white matter, particularly in common sites of lacunar infarction ([@B12]). There is also a report of a patient with chronic GVHD who presented only brain atrophy at an earlier stage of the disease ([@B14]). After hematopoietic cell transplantation, leukoencephalopathy can also be caused by many immunosuppressants, radiation therapy, and opportunistic infections. The magnetic resonance appearance of these forms of toxic leukoencephalopathy involves symmetric hyperintense lesions in the white matter on T2WI and FLAIR, which are associated with the foci of restricted diffusion within these areas. Typically, there is no associated contrast enhancement ([@B23]). The perivascular spaces (Virchow-Robin spaces) are not normally enhanced with gadolinium ([@B24]). In the present case, punctate and curvilinear gadolinium enhancement (PCGE) was found along the path of the perforating medullary arteries. Similar findings were also reported by Sostak et al ([@B10]). PCGE may be seen when the blood-brain barrier (BBB) of the small vessels is disrupted, either by the direct injury of the endothelial cells or by angiocentric infiltrates composed of various combinations of T lymphocytes, B lymphocytes, and histiocytes. A brain biopsy should be performed to determine the phenotypes of the infiltrating cells and assess EBV reactivation to distinguish between posterior reversible encephalopathy syndrome (PRES), primary angiitis of the CNS (PACNS), demyelinating disease, immune reconstitution inflammatory syndrome (IRIS), lymphomatoid granulomatosis (LYG), and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) ([@B25]). The pathogenesis of CNS-cGVHD may be similar to these diseases, as is indicated by their similar radiological findings. In recent years, integrins have also been implicated in the pathogenesis of intestinal GVHD. Anti-alpha4 integrin therapy has now been approved by the Food and Drug Administration (FDA) for the treatment of multiple sclerosis and inflammatory bowel disease. Drugs that block the infiltration of leukocytes via the BBB could also be effective for CNS-cGVHD.

The post-transplantation survival periods are expected to increase with advancements in transplantation technology. It is important to bear in mind that patients receiving HLA-mismatched transplantation, patients with a history of calcineurin inhibitor-induced immune suppression, and patients receiving TBI, whole-brain irradiation, or intrathecal injections are at risk for developing late-onset neurological complications. As a result, neuropsychological tests must occasionally be performed to closely monitor the higher brain function and neurological symptoms of these patients ([@B26]). Chronic GVHD is particularly difficult to diagnose because it can develop over years and sometimes only involves the CNS. MRI is useful for detecting distinct lesions that are localized to the CNS. In other words, MRI gives us a clue as to whether a brain biopsy is required for a patient who is suspected of having chronic GVHD; this makes MRI the key to facilitating the early and definitive diagnosis of chronic GVHD and to delivering effective treatment in a timely manner.

The authors state that they have no Conflict of Interest (COI).
===============================================================

This work was supported by JSPS KAKENHI Grant number JP 26460901.

[^1]: Correspondence to Dr.　Kiyotaka Nakamagoe, <nakamagoek@md.tsukuba.ac.jp>
